The words and actions of US President Donald Trump are rocking the pharmaceutical industry. On May 5, he said he…
REGULATORY
Chuikyo Subcommittee OKs Basic SaMD Reimbursement Rule
The Central Social Insurance Medical Council’s (Chuikyo) medical materials subcommittee basically approved the outlines of the evaluation rules for software as a medical device (SaMD) under health insurance programs on November 12. Based on examples in the past, SaMD that…
To read the full story
Related Article
- Chuikyo OKs FY2022 Drug Pricing Reform Outline; Spillover Exclusion, Mega Seller Rule
December 23, 2021
- Public-Private Collaboration Needed to Refine SaMD Regulatory System
November 26, 2021
- Trade Groups Urges New Reimbursement Fee Evaluation for SaMD
August 26, 2021
- Chuikyo to Compile Proposal on SaMD Reimbursement by Year-End
August 5, 2021
- Chuikyo to Discuss Evaluation Rule for SaMD toward Next Reimbursement Reform
May 27, 2021
REGULATORY
- Pfizer’s UC Drug, MSD’s PAH Therapy, and More Up for Panel Review on June 4
May 22, 2025
- MHLW Orders Label Revisions for Diuretics, Zolgensma
May 22, 2025
- LDP Generic League Calls for Necessary Pricing Steps to Ensure Quality and Supply
May 22, 2025
- MHLW Working Group Begins Discussions to Update List of “Stable Supply Medicines”
May 22, 2025
- OTC-Like Drug Is Hardest Topic in Tripartite Social Security Talks: Japan PM
May 22, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…